" class="no-js "lang="en-US"> ACROMEC - Medtech Alert
Tuesday, April 16, 2024

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
ACROMEC | Pharmtech Focus

ACROMEC

About ACROMEC

ACROMEC

We are an established specialist engineering services provider in the field of controlled environments.
Our expertise is in the design and construction of facilities requiring controlled environments such as Design Engineering, Procurement, and Construction of Cleanroom, high containment Laboratory, and complex Healthcare facility in Singapore and Asia.

Related Story

News

 ACROMEC's Associated Life Science Incubator Launches Co-working Labspace | Pharmtech Focus

ACROMEC's Associated Life Science Incubator Launches Co-working Labspace

September 24 2021

ACROMEC Limited (ACROMEC; SGX: 43F), a specialist engineering services provider, announced that subsidiary ACROMEC Engineers […]